Document is current
Any future updates will be listed below
-
Authors
Levy, Tess https://orcid.org/0000-0003-2207-0440
Pichardo, Thariana https://orcid.org/0009-0005-6792-0156
Silver, Hailey https://orcid.org/0000-0003-4630-1071
Lerman, Bonnie https://orcid.org/0000-0002-9032-1224
Zweifach, Jessica https://orcid.org/0000-0001-5392-8839
Halpern, Danielle https://orcid.org/0000-0001-6745-1197
Siper, Paige M. https://orcid.org/0000-0002-9659-8232
Kolevzon, Alexander https://orcid.org/0000-0001-8129-2671
Buxbaum, Joseph D. https://orcid.org/0000-0001-8898-8313
-
Funding
Funding for this research was provided by:
Beatrice and Samuel A. Seaver Foundation
- License Information
-
More Information
Article History
Received: 11 April 2023
Accepted: 2 June 2023
First Online: 16 July 2023
Declarations
:
: T.L is on the Scientific Advisory Board for the CHAMP1 Foundation. A.K. is on the Advisory Board for the Klingenstein Third Generation Foundation, Ovid Therapeutics, David Lynch Foundation, ADNP Kids Research Foundation, and Ritrova Therapeutics and consults to Acadia, Alkermes, Jaguar Therapeutics, GW Pharmaceuticals, Neuren Pharmaceuticals, Scioto Biosciences, and Biogen. P.M.S. consults to Deerfield. J.D.B. consults to BridgeBio and to Rumi, holds a patent for IGF-1 in Phelan-McDermid syndrome, holds an honorary professorship from Aarhus University Denmark, receives research support from Takeda and Oryzon, and is a journal editor for Springer Nature. The other authors declare no financial interests.
: This study was performed in line with the principles of the Program for Protection of Human Subjects at the Icahn School of Medicine at Mount Sinai.
: Written informed consent was obtained from all participant’s parents or legal guardians in the study.
